PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Election Fraud Prosecution at an ‘All-Time High’: Texas Attorney General’s Office

Show Me

We Were Told That Election 2020 Reports Of Late Night Ballot Drops In White Vans In Multiple States During After The Deadline Was A “Conspiracy Theory” | The Only Problem Was More Video Was Discovered Showing Late Night/Early Morning Ballot Drops 8 Hours After The Deadline | Video: 7 Minutes 21 Seconds

Show Me

Exclusive: Suspicious Vehicle Seen Escorting Late Night Election 2020 Biden Ballot Van at TCF Center

Show Me

They Banned Discussion Of Possible Election Fraud Via Computer Systems While “533 Million Facebook Users Had Private Information Leaked Today, Zuckerberg Knew In January And Did Nothing” | Wonder Why. . .

Show Me

One Of The Biggest Media Loudmouths Opposing Even The Thought That Computer Systems Can Be Hacked In An Election, Gets Hacked | “Statement From Atlantic Media on Unauthorized Access of Its Servers”

Show Me

Mainstream Media Debunked Again | “Pennsylvania Forced to Remove 21,000 Dead People Off Its Voter Rolls: Settlement”

Show Me

Giuliani Denies Defaming Dominion Voting With Election Claims

Show Me

Dan Crenshaw Debunks Liberal ‘Racist’ ID Claims with Joe Rogan

Show Me

If You Think Matt Gaetz Is Targeted Because He’s Heterosexual, Think Again | Gaetz Is Targeted Because He’s Feared By The Left | It’s Interesting To Look Back & Hear Rep. Gaetz and Bernie Kerik Discuss Election Fraud & Impeachment Issues and It’s Importance Moving Forward | Video: 8 Minutes 51 Seconds

Show Me

NJ City Councilman Accused of Mail-In Voting Fraud Pleads Not Guilty

Show Me

Paterson councilman Alex Mendez pleads not guilty to voter fraud charges

Show Me

California Mayor Resigns After Pleading Guilty to Election Fraud

Show Me

Biden-Voting County Sees 5 Charged for Election Fraud.

Show Me

24 More Charged in Voter-Fraud Probe, Prosecutors Say

Show Me

Monsanto Case Reveals That Power Conspiracies On A Massive Scale Do Happen | Think Election 2020 Fraud

Show Me

Disparate treatment in two fund-raising fraud cases renews debate over dual Justice system

Show Me

Notary Was Arrested, Charged With Voter Fraud In Connection With Aberdeen Alderman Election

Show Me

Mayor Pro Tem of California City Resigns After Pleading Guilty to Election Fraud

Show Me

Finding of Absentee Ballot Fraud in local Mississippi race requires a new election

Show Me

‘We’re Living in a Gigantic Lie’ – Dennis Prager Talks Free Speech | American Thought Leaders | Video: 47 Minutes 32 Seconds

Show Me

American Center For Law & Justice | Fmr CDC Dir. Confirms Conservative “Conspiracy Theory” is Highly Likely | Video: 4 Minutes 6 Seconds

Show Me

Ex-CDC Director Says He Believes Coronavirus Escaped from a Chinese Lab

Show Me

Scientists Issue Open Letter Detailing Incorrect and Contradictory Claims in WHO Origins Report Used to Downplay Lab Leak Theory

Show Me

WHO buries dismissal of lab leak theory in last pages of 123-page origins report, draft copy shows

Show Me

Washington Examiner: John Durham Interviewing Witnesses And Subpoenas

Show Me

Epidemiologist: We Could Have Reached Natural Herd Immunity in 6 Weeks | Video: 1 Hour 12 Minutes 27 Seconds

Show Me

The Most Melancholy Comet We’ve Ever Seen

Show Me

Dozens of Plaintiffs Demand Day in Court Against Monsanto as Bayer Tries to Reassure Investors

Show Me

Brazil’s COVID-19 death toll to surpass that of worst U.S. wave

Show Me

Manchin Vows to Uphold Filibuster, Complicating Biden’s Agenda

Show Me

Steven Crowder’s Latest Video Has The Internet Going Absolutely Ballistic

Show Me

COVID vaccination site closes early after adverse reactions to Johnson & Johnson shot

Show Me

In Michigan, 246 fully vaccinated people tested positive for COVID-19, three died

Show Me

Biden Commerce Secretary Says Trump’s Steel and Aluminum Tariffs Saved American Jobs

Show Me

April 7, 2021 | Nightly News Rebroadcast | Video: 46 Minutes

Show Me

Shh. These Are The Constant Mass Shootings We’re Not Supposed To Talk About | “2-Year-Old Boy, 7 Adults Wounded in Latest Chicago Shootings”

Show Me

Democrat Run States & Cities Continue To Struggle With Covid-19 | “Minnesota hospitalizations climb as virus cases trend upward”

Show Me

Official: EU agency to confirm AstraZeneca blood clot link

Show Me

NASA gets first weather report from the Jerezo Crater Mars using a system strapped to Perseverance

Show Me

What to Know About the Facebook Data Leak

Show Me